Black Diamond Therapeutic Q2 EPS $(0.52) Beats $(0.54) Estimate. Cash and Equivalents $89.5M
Portfolio Pulse from Benzinga Newsdesk
Black Diamond Therapeutic (NASDAQ:BDTX) reported Q2 losses of $(0.52) per share, beating the analyst consensus estimate of $(0.54) by 3.7%. This is a 17.46% increase over losses from the same period last year. The company also reported cash and equivalents of $89.5M.
August 11, 2023 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Black Diamond Therapeutic reported better than expected Q2 losses and an increase in cash and equivalents. This could potentially lead to a positive market reaction.
Black Diamond Therapeutic reported a smaller loss than expected, which is generally seen as positive by the market. Additionally, the company's cash and equivalents have increased, indicating a strong financial position. These factors could lead to a positive market reaction in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100